FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically to using recombinant proteins for treating mammals suffering malignancies. A method of treating involves the injections of an antitumour agent of a protein factor specific to malignant cells. The antitumour agent is presented by a recombinant peptide of molecular weight approximately 16 kDa containing methionine residue, a fragment of human kappa casein of 24 to 134 amino acid residue and C-terminal histidine tract. The agent is introduced intravenously daily in dose 8-100 mg/kg of body weight; the therapeutic course is 2-6 days.
EFFECT: invention allows higher effectiveness of antitumour therapy.
5 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PLASMID pET-15b_T3_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING ANTI-TUMOR ACTIVITY AGAINST HUMAN BREAST CANCER | 2016 |
|
RU2619053C1 |
| RECOMBINANT PLASMID pET-15b_T1_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING CYTOTOXIC ACTIVITY AGAINST CANCER CELLS AND TARGETED PROPERTIES AGAINST TUMOR TISSUE | 2016 |
|
RU2619050C1 |
| RECOMBINANT EL1 PEPTIDE HAVING CYTOTOXIC ACTIVITY RELATIVE TO HUMAN CANCER CELLS | 2017 |
|
RU2683221C1 |
| METHOD OF SUPPRESSING GROWTH OF TUMOURS WITH GENETICALLY MODIFIED VERSION OF TRAIL CYTOKINE | 2019 |
|
RU2727059C1 |
| ANTI-TUMOUR AGENT BASED ON RECOMBINANT VACCINIA VIRUS STRAIN AND METHOD FOR PRODUCTION THEREOF | 2019 |
|
RU2730657C1 |
| METHOD FOR EXTRACTING AND PURIFYING RECOMBINANT PROTEIN, AN ANALOGUE OF A HUMAN KAPPA-CASEIN FRAGMENT HAVING CYTOTOXIC ACTIVITY TOWARDS HUMAN CANCER CELLS | 2018 |
|
RU2693251C1 |
| METHOD OF SUPPRESSING TUMOUR GROWTH | 2012 |
|
RU2530592C2 |
| FRACTION OF DNA-HYDROLYSE SECRETORY IMMUNOGLOBULINS OF CLASS A, WITH SELECTIVE APOPTOTIC ACTIVITY IN RELATION TO HUMAN CANCER CELLS | 2015 |
|
RU2605321C1 |
| METHOD FOR TREATING MALIGNANT TUMORS | 2004 |
|
RU2271209C1 |
| ANGIOGENESIS INHIBITOR, ANTI-ANGIOGENIC PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT OF MALIGNANT NEOPLASM | 2005 |
|
RU2287341C1 |
